DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eliana Merle - 2 Merle - 2 steatohepatitis - 1 Akero - 1 Nash - 1 NASH - 1 NASH cirrhotics - 1 — CNBC's Michael Bloom - 1
Top related locs:
U.S Nash Moderna Friday's CMV
Top related orgs:
U.S . Food - 1 Drug Administration - 1 Therapeutics - 1 UBS - 1 Moderna - 1 UBs - 1

Search resuls for: "Eliana Merle"


4 mentions found


☆ This biotech stock can rally more than 70% with its fatty liver disease treatment, UBS says
  + stars: | 2023-08-28 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
Akero Therapeutics could be a winner in the race to treat non-alcoholic steatohepatitis, a potentially life-threatening liver disease. Nash is a severe form of fatty liver disease which can cause inflammation of the liver and fibrosis, or scarring, of the liver. The disease can also lead to cirrhosis, in which the liver is permanently damaged. Individuals with Nash are part of the 20% of adults in the U.S. who have NAFLD, or non-alcoholic fatty liver disease. AKRO YTD mountain Akero Therapeutics stock.
Persons: steatohepatitis, Eliana Merle, Akero, Nash, NASH, Merle, NASH cirrhotics, — CNBC's Michael Bloom Organizations: U.S . Food, Drug Administration, Therapeutics Locations: U.S, Nash
☆ UBS upgrades Moderna, says potential from new vaccines is underappreciated
  + stars: | 2023-06-26 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
Investors aren't fully appreciating the broader uses for Moderna's mRNA vaccines, creating a big buying opportunity, UBS said Monday. UBS did lower its price target to $191 from $221, though the new forecast implies upside of 61% from Friday's close. MRNA YTD mountain Moderna stock has declined nearly 35% so far this year. Merle pointed toward vaccines for respiratory syncytial virus (RSV), the flu and cytomegalovirus (CMV) as promising upside drivers for the company. "We think MRNA's CMV vaccine could be a major potential upside driver over the next 1-2 years, with limited priced in (leading cause of birth defects, no approved vaccines)," Merle said.
Persons: Eliana Merle, Merle, Michael Bloom Organizations: UBS, Moderna, UBs Locations: Moderna, Friday's, CMV
☆ This under-the-radar biotech stock is an overlooked buying opportunity that could almost double, UBS says
  + stars: | 2023-01-19 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
CureVac N.V. is an "underappreciated" buying opportunity, according to UBS. CureVac said this month that it plans to hold further patient trials of its mRNA vaccines for Covid-19 and the flu. But CureVac has surged more than 50% this year, and the UBS analyst expects the stock has further to climb. Her $18 price target, up from $8, implies the shares can surge roughly 90% from Wednesday's closing price. We note additional Ph1 data is expected near-term," the UBS analyst wrote.
☆ These are the top 10 stock plays for 2023, according to UBS
  + stars: | 2022-12-14 | by ( Carmen Reinicke | ) www.cnbc.com   time to read: +5 min
As the year winds down, investors are looking forward to 2023 and wondering where they should place their top bets. Analysts that cover companies are mulling the same question, prompting UBS to put together a list of its top conviction picks for 2023. The stock which is poised for the largest gain is Kymera Therapeutics , a biotechnology firm that UBS thinks could surge 240% to its target price. She added that UBS expects updates across all four programs in the near term as well as over 2023. Analysts that cover companies are mulling the same question, prompting UBS to put together a list of its top conviction picks for 2023.
0 next >>
Total: 4